DE:1YR Stock Latest News
Company AnnouncementsImmunovia Publishes Prospectus for SEK 63.4 Million Rights Issue1w ago
Company AnnouncementsImmunovia’s PancreaSure Data Selected for Presidential Plenary1w ago
Company AnnouncementsImmunovia Reports Stronger PancreaSure Sales in Third Quarter1w ago
Company AnnouncementsImmunovia Sets Q3 2026 Report Release and Investor Webcast2w ago
Company AnnouncementsImmunovia Secures Shareholder Backing for Major Rights Issue and Capital Structure Changes2w ago
Company AnnouncementsImmunovia Sets Final Terms for Discounted Rights Issue to Fund PancreaSure Push2w agoCompany AnnouncementsImmunovia Builds Case for PancreaSure in Hereditary High-Risk Pancreatic Cancer Market1M ago
- Company AnnouncementsImmunovia Calls Extraordinary Meeting to Enable Flexible Rights Issue1M ago
Company AnnouncementsImmunovia Seeks Medicare Coverage for PancreaSure Pancreatic Cancer Test1M ago
Company AnnouncementsImmunovia Survey Shows Strong Demand for Blood-Based Pancreatic Cancer Tests3M ago
Company AnnouncementsImmunovia AB Earnings Call: Early Traction, Funding Risks3M ago
Company AnnouncementsImmunovia boosts PancreaSure uptake as clinical evidence builds and cash burn stays below guidance3M agoCompany AnnouncementsImmunovia to Present Q2 2026 Report Amid Push in Pancreatic Cancer Diagnostics3M ago
Company AnnouncementsImmunovia’s PancreaSure Test Posts Strong Late-Stage Pancreatic Cancer Data in AFFIRM Study5M ago
Company AnnouncementsImmunovia AGM Backs New Share Issue Mandate and Major Option Program6M ago
Company AnnouncementsImmunovia Cuts Cash Burn as PancreaSure Expansion Nears Full U.S. Coverage6M ago- Company AnnouncementsImmunovia Cuts Cash Burn as PancreaSure U.S. Rollout Nears Nationwide Reach6M ago
Company AnnouncementsImmunovia Launches ASSURE Registry to Drive Real-World Adoption of PancreaSure6M agoCompany AnnouncementsImmunovia Publishes 2025 Annual Report Focused on Pancreatic Cancer Diagnostics7M ago
